Hawley Demands Answers from FDA Following Reports Agency Delayed Review of Mifepristone

For information about Senator Hawley’s new RECA law to compensate Missourians,click here.
Wednesday, December 10, 2025
WASHINGTON— Today, U.S. Senator Josh Hawley (R-Mo.)senta letter to Food and Drug Administration (FDA) Commissioner Marty Makary followingreportsthat he ordered the agency to delay a review of the chemical abortion drug mifepristone.
Senator Hawley wrote,“Six months ago, you told me you were “committed to conducting a review of mifepristone,” the chemical abortion drug. You repeated this commitment to state attorneys general and other members of Congress. Yet according to news reports yesterday, you have ordered this promised safety review delayed until after the midterms. Indeed, it is unclear whether you are conducting an independent safety review at all.”
“This is totally unacceptable. I cannot emphasize enough the danger of playing politics with women’s health. In President Trump’s first term, HHS required an in-person visit with a licensed physician before dispensing the chemical abortion drug. The safety rules also required in-person dispensing of the drug in a clinical setting. But Joe Biden removed those guardrails,”Senator Hawley continued.“The safety regulations from President Trump’s first term should be reinstated. But you have not done so. And news reports indicate you are attempting to sideline any review of mifepristone safety.”
Senator Hawley firstsent a letterto Commissioner Makary after he stated the FDA had “no plans to take action” on mifepristone. In his response, Makary assured Senator Hawley that he was “committed to conducting a review of mifepristone.” Months later, the FDA inexplicably approved a new generic abortion drug. Senator Hawley sent Commissioner Makaryanother letterin October, questioning the timing of that decision after Makarycommittedto conducting a full review of the chemical abortion drug.
Read the full letterhereor below.
Dr. Marty MakaryCommissionerU.S. Food and Drug Administration10903 New Hampshire AvenueSilver Spring, MD 20993Commissioner Makary:Six months ago, you told me you were “committed to conducting a review of mifepristone,” the chemicalabortion drug. You repeated this commitment to state attorneys general and other members of Congress.Yet according to news reports yesterday, you have ordered this promised safety review delayed until afterthe midterms. Indeed, it is unclear whether you are conducting an independent safety review at all.This is totally unacceptable. I cannot emphasize enough the danger of playing politics with women’s health.In President Trump’s first term, HHS required an in-person visit with a licensed physician before dispensingthe chemical abortion drug. The safety rules also required in-person dispensing of the drug in a clinicalsetting. But Joe Biden removed those guardrails. Now, new studies from more than 865,000 insuranceclaims report that nearly 11% of women using mifepristone suffer a serious adverse health event—likesepsis or hemorrhaging—within 45 days. That is 22 times the likelihood of risk currently listed onmifepristone’s “black box” warning. The safety regulations from President Trump’s first term should bereinstated.But you have not done so. And news reports indicate you are attempting to sideline any review ofmifepristone safety. In fact, you have repeatedly wavered in public on whether you are conducting a safetyreview at all. On April 24, you told an interviewer you had “no plans to take action” on mifepristone. Youwrote to me on June 2, however, that you were “committed to conducting a review of mifepristone.” Then,a few months later, you reversed course again and inexplicably approved a new generic abortion drug, withno meaningful safety guardrails or conditions. Despite your claims to the contrary, that approval was in noway compelled by law.Yesterday, in response to the latest reports, you said, “There has been an ongoing review of mifepristone.It’s actually required as part of a policy called REMS.” But that is not what you promised. You promiseda new and comprehensive study taking account of all available safety data, not the standard monitoringFDA already performs for countless drugs.
There are more abortions in America now than when Roe was still law. And this is largely because of thechemical abortion drug and its generics, like the one you approved. Chemical abortions account for almost70 percent of all abortions nationwide. The science is clear. The chemical abortion drug is not safe.It is time for direct answers about what, precisely, FDA is doing. Please answer the following questions byno later than Monday, December 15, 2025:
I await your responses.
Sincerely,Josh HawleyUnited States Senator

"*" indicates required fields
381 Russell Senate Office BuildingWashington, D.C. 20510Office: 202-224-6154Fax: 202-228-0526
1123 Wilkes Blvd, Suite 220Columbia, MO 65201Office: 573-554-1919Fax: 573-256-1805
400 E. 9th Street, Suite 9350Kansas City, MO 64106Office: 816-960-4694Fax:816-472-6812
3236 E. Ridgeview StreetSpringfield, MO 65804Office: 417-869-4433
530 Maryville Centre DriveSuite 460St. Louis, MO 63141Office: 314-354-7060Fax: 1 314-436-8534
555 Independence Street, #1600Cape Girardeau, MO 63703Office: 573-334-5995Fax: 573-334-5947